ABSTRACT
IMPORTANCE Identifying potential Covid-19 patients in the general population is a huge challenge at the moment. Given the low availability of infected Covid-19 patients clinical data, it is challenging to understand and comprehend similar and complex patterns in these symptomatic patients. Laboratory testing for Covid19 antigen with RT-PCR | (Reverse Transcriptase) is not possible or economical for whole populations.
OBJECTIVE To develop a Covid risk stratifier model that classifies people into different risk cohorts, based on their symptoms and validate the same.
DESIGN Analysis of Covid cases across Wuhan and New York were done to identify the course of these cases prior to being symptomatic and being hospitalised for the infection. A dataset based on these statistics were generated and was then fed into an unsupervised learning algorithm to reveal patterns and identify similar groups of people in the population. Each of these cohorts were then classified and identified into three risk levels that were validated against the real world cases and studies.
SETTING The study is based on general population.
PARTICIPANTS The adult population were considered for the analysis, development and validation of the model
RESULTS Of 1 million observations generated, 20% of them exhibited Covid symptoms and patterns, and 80% of them belonged to the asymptomatic and non-infected group of people. Upon clustering, three clinically obvious clusters were obtained, out of which the Cluster A had 20% of the symptomatic cases that were classified into one cohort, the other two cohorts, Cluster B had people with no symptoms but with high number of comorbidities and Cluster C had people with few leading indicators for the infection with few comorbidities. This was then validated against 300 participants whose data we collected as a part of a research study through our Covid-research tool and about 92% of them were classified correctly.
CONCLUSION A model was developed and validated that classifies people into Covid risk categories based on their symptoms. This can be used to monitor and track cases that rapidly transition into being symptomatic which eventually get tested positive for the infection in order to initiate early medical interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was self funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have followed all the ethical procedures and protocols to anonymise, store and handle the patient level data. This research was approved by the clinical and engineering advisory board at Cohere-Med Inc.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This work used synthetic data generated from studies. For internal and external validation, open data sources were used.
https://www.kaggle.com/rupsikaushik/covid19-patientlevel-data
